Last updated on June 2019

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma


Brief description of study

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. Part B of the study will assess the efficacy and safety of two different Betalutin/lilotomab dosing regimens in adult patients with relapsed rituximab / anti-CD20-refractory follicular lymphoma who have received 2 or more prior therapies.

Clinical Study Identifier: NCT01796171

Find a site near you

Start Over

Clinical Trials

Reggio Emilia, Italy
  Connect »